Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 8

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 8
---
 for the Company via the production and supply of DNA critical starting materials and
RNAP to produce mRNA therapies.

In August 2022, the Company launched
DNA IVT templates manufactured via its LineaDNA platform that have resulted in evaluations of the Company’s IVT templates by numerous
therapeutic developers and CDMOs in the United States and the Asia-Pacific. In addition, the Company’s IVT templates are currently
under late-stage evaluations by two therapeutic developers and one CDMO for use as DNA templates for the production of mRNA intended
for clinical use in calendar year 2025. However, there can be no assurance that related contracts will be entered into. In response to
this demand, the continued growth of the mRNA therapeutic market, and the unique abilities of the LineaDNA platform, the Company acquired
Spindle Biotech, Inc. (“Spindle”) in July 2023 to potentially increase its mRNA-related total addressable market (“TAM”)
to include the manufacture and sale of RNAP for use in conjunction with our LineaDNA IVT templates.

Through our acquisition of Spindle, we launched
our Linea IVT platform in July 2023, which combines Spindle’s proprietary high-performance RNAP, now marketed by the Company
as Linea RNAP, with our enzymatically produced LineaDNA IVT templates. We believe the Linea IVT platform enables our customers to make
better mRNA, faster. Based on data generated by the Company, we believe the integrated Linea IVT platform offers the following advantages
over conventional mRNA production to therapy developers and manufacturers:

| · | The prevention or reduction                                                                                                   
 of double stranded RNA (“dsRNA”) contamination resulting in higher target mRNA yields with the potential to reduce downstream 
 processing steps. dsRNA is a problematic immunogenic byproduct produced during conventional mRNA manufacture;                 |

<div align='center'>3</div>

| · | delivery of IVT templates                                               
 in as little as 14 days for milligram scale and 30 days for gram scale; |

| · | reduced mRNA manufacturing 
 complexities; and          |

| · | potentially enabling mRNA                                         
 manufactures to produce mRNA drug substance in less than 45 days. |

According to the Company’s internal
modeling, the ability to sell both LineaDNA IVT templates and Linea RNAP under the Linea IVT platform potentially increases the Company’s
mRNA-related TAM by approximately 3-5x as compared to selling LineaDNA IVT